Template:Cryptococcus Meningitis: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
===Meningitis (not AIDs associated)=== | ===Meningitis (not AIDs associated)=== | ||
*Amphotericin B 0.7-1mg/kg IV q24hrs | *Amphotericin B 0.7-1mg/kg IV q24hrs '''AND''' Flucytosine 25mg/kg PO q6hrs x 4 weeks | ||
**Followed by Fluconazole 400mg PO q24hrs x 8 weeks | **Followed by Fluconazole 400mg PO q24hrs x 8 weeks | ||
===Meningitis (with AIDS)=== | ===Meningitis (with AIDS)=== | ||
*Amphotericine B 0.7 | *Amphotericine B 0.7-1mg/kg IV q24hrs '''AND''' Flucytosine 25mg/kg PO q6hrs x 2 weeks | ||
**Followed by Fluconazole 400mg PO q24hrs x 8 weeks | **Followed by Fluconazole 400mg PO q24hrs x 8 weeks | ||
*Initiation of HAART is delayed by 2 to 10 weeks to minimize the risk of immune reconstitution syndrome | *Initiation of HAART is delayed by 2 to 10 weeks to minimize the risk of immune reconstitution syndrome | ||
Revision as of 06:35, 6 March 2019
Meningitis (not AIDs associated)
- Amphotericin B 0.7-1mg/kg IV q24hrs AND Flucytosine 25mg/kg PO q6hrs x 4 weeks
- Followed by Fluconazole 400mg PO q24hrs x 8 weeks
Meningitis (with AIDS)
- Amphotericine B 0.7-1mg/kg IV q24hrs AND Flucytosine 25mg/kg PO q6hrs x 2 weeks
- Followed by Fluconazole 400mg PO q24hrs x 8 weeks
- Initiation of HAART is delayed by 2 to 10 weeks to minimize the risk of immune reconstitution syndrome